PolyPid (PYPD) Common Equity (2019 - 2026)
PolyPid (PYPD) posted Common Equity of $8.8 million for Q1 2026, down 19.99% sequentially from $11.0 million in Q4 2025, and up 10109.3% YoY from N/an in Q1 2025.
PolyPid (PYPD) Common Equity (2019 - 2026) Analysis & Trends
PolyPid has reported Common Equity for 8 years, with the latest figure at $8.8 million in Q1 2026.
- Quarterly Common Equity rose 10109.3% year-over-year to $8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.8 million (up 10109.3% YoY) and the FY2025 annual result came in at $11.0 million, up 42.8% from the prior year.
- Common Equity eased to $8.8 million in Q1 2026 per PYPD's latest filing, from $11.0 million in the prior quarter.
- Over five years, Common Equity peaked at $28.8 million in Q1 2022 and troughed at -$2.1 million in Q4 2023.
- A 5-year average of $9.5 million and a median of $8.3 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2026: Common Equity sank 135.96% in 2023, then surged 10109.3% in 2026.
- Over 5 years, Common Equity stood at $5.8 million in 2022, then slumped by 135.96% to -$2.1 million in 2023, then jumped by 466.6% to $7.7 million in 2024, then jumped by 42.8% to $11.0 million in 2025, then fell by 19.99% to $8.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $8.8 million, $11.0 million, and $15.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | PolyPid | 113.30 Mn | 106.53 Mn | - | 5.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.39 Mn |
| Mar 31, 2026 | 8.78 Mn |
| Dec 31, 2025 | 10.97 Mn |
| Sep 30, 2025 | 15.37 Mn |
| Jun 30, 2025 | 20.48 Mn |
| Mar 31, 2025 | 86,000.00 |
| Dec 31, 2024 | 7.68 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | 7.15 Mn |
| Dec 31, 2023 | -2.10 Mn |
| Sep 30, 2023 | 3.54 Mn |
| Jun 30, 2023 | 8.35 Mn |
| Mar 31, 2023 | 11.41 Mn |
| Dec 31, 2022 | 5.83 Mn |
| Sep 30, 2022 | 11.50 Mn |
| Jun 30, 2022 | 19.11 Mn |
| Mar 31, 2022 | 28.85 Mn |
| Dec 31, 2021 | 35.96 Mn |
| Sep 30, 2021 | 48.12 Mn |